KRT18 and metabolic dysfunction-associated steatotic liver disease: Specifically, we evaluated the discriminatory performance of serum CK18‐M30 and CK18‐M65 for identifying NAFLD patients with CHD and explored the molecular plausibility of a CK18‐mediated liver–heart axis.